Anticancer Therapies – Webinars and Online Events

Using the example of tumor-associated macrophages (TAMs), this webinar takes a closer look at immune cells in the tumor microenvironment (TME), helping us to gain a better understanding of how specific subtypes and their reprogramming may influence therapy efficiency.

Speaking at Cell & Gene Therapy 2023,Tracy Zhao from ACROBiosystems, presented their talk on products and services across cell therapy research and development.

In this webinar, we will guide you through the essential steps of the CAR T workflow while emphasizing the critical role of in-process control and quality control.

Our expert speaker will discuss the current market presence of CAR T cells and the market potential for cell therapy research.

Speaking at The Landscape of Cancer Research 2022, Nicholas Abuid, PhD from ACROBiosystems, presented his talk on providing high purity, customizable, and bioactive reagents to support research and translation in cancer immune therapy. Their catalogue ranges in targets for various diseases.

Do you want to bring your CAR T-cell research into clinical applications?

Watch this webinar and explore Miltenyi Biotec’s solutions to advance CAR T-cell therapies – from basic research to process development and clinical manufacturing. Discover the products, tools and services that build on Miltenyi Biotec’s expertise to move your CAR T-cell projects forward.

Combining both real-time live-cell imaging with biosensor-based impedance measurements is now possible for the first time, providing a multi-parametric, information-rich cellular analysis.

In this webinar you will learn how the power of large-scale proteomics can be leveraged for multiple divergent applications in the field of oncology.

Cell-based chimeric antigen receptor (CAR) T cell therapies have rapidly advanced in recent years, with a variety of targets in clinical research and several FDA approved products already on the market.

Cell therapy is a transformative cancer treatment that utilizes genetically modified cells from a healthy donor or patient's own immune system to attack cancer cells, but manufacturing these cells represents a major challenge for the industry.